These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37860199)

  • 41. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
    Di Lauro V; Barchiesi G; Martorana F; Zucchini G; Muratore M; Fontanella C; Arpino G; Del Mastro L; Giuliano M; Puglisi F; De Laurentiis M
    ESMO Open; 2022 Dec; 7(6):100629. PubMed ID: 36399953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.
    Schettini F; Seguí E; Conte B; Sanfeliu E; Gonzalez-Farre B; Jares P; Vidal-Sicart S; Ganau S; Cebrecos I; Brasó-Maristany F; Muñoz M; Prat A; Vidal M
    Front Oncol; 2022; 12():1009352. PubMed ID: 36425558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
    Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
    Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 46. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
    Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
    ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
    Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
    Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
    Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.
    Bayraktar S; Batoo S; Al-Hattab E; Basu S; Okuno S; Glück S
    Future Oncol; 2020 Nov; 16(32):2661-2672. PubMed ID: 32805138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.
    Edessa D; Sisay M
    Breast Cancer (Dove Med Press); 2017; 9():567-579. PubMed ID: 29263697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Burris HA
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
    Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
    Iorfida M; Mazza M; Munzone E
    Breast Cancer (Dove Med Press); 2020; 12():45-56. PubMed ID: 32256106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis.
    Leung JH; Leung HWC; Wang SY; Huang SS; Chan ALF
    Expert Opin Drug Saf; 2021 Aug; 20(8):949-957. PubMed ID: 34047239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case report:
    Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
    Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.